Multiple Sclerosis treatment

Clinical Trials in: Mexico, Argentina, Colombia and Brazil.

Locally-Based, Full Service CRO

Contact us today to learn more.

+ 0
Sites Throughout LATAM
+ 200
Patients in our network
+ 0
Conducted Studies
0 %
Lost-to-Follow Up rate
Multiple Sclerosis treatment
As a leading CRO in LATAM, we specialize in supporting clinical trials throughout the region. Our extensive experience and broad network of clinical sites enable us to execute trials with speed and efficiency, ensuring high patient recruitment and retention rates.

Multiple Sclerosis treatment

Multiple Sclerosis treatment trials in Latin America 2023 – Cohortias the CRO of LATAM

Multiple Sclerosis (MS) is a chronic and disabling disease of the central nervous system that affects more than 2.3 million people worldwide, according to the Multiple Sclerosis International Federation.

It is a complex and unpredictable disease, which makes it difficult to diagnose and treat effectively. Despite this, there have been significant advances in the development of treatments for MS in recent years. Latin America, in particular, has been the site of several important Multiple Sclerosis treatment trials.

One of the most promising areas of research in Multiple Sclerosis treatment is the development of disease-modifying therapies (DMTs). These drugs are designed to slow down the progression of the disease and reduce the number and severity of relapses. DMTs work by targeting the immune system, which is believed to play a key role in the development and progression of MS.

In 2023, Latin America is home to several ongoing clinical trials investigating the efficacy and safety of various DMTs. These trials involve thousands of patients across the region and are being conducted by leading researchers and clinicians in the field of MS.

One of the most promising DMTs currently being tested in Latin America is ocrelizumab. This drug works by targeting B cells, a type of immune cell that is thought to contribute to the development and progression of MS. In clinical trials, ocrelizumab has been shown to significantly reduce the risk of relapse and slow down the progression of disability in patients with MS.

Another DMT that is being tested in Latin America is cladribine. This drug works by targeting the lymphocytes, a type of immune cell that is believed to play a key role in the development of MS. In clinical trials, cladribine has been shown to significantly reduce the number of relapses and slow down the progression of disability in patients with MS.

In addition to these DMTs, there are several other drugs being tested in Latin America for the treatment of MS. These include alemtuzumab, which targets the immune system by depleting certain types of white blood cells, and fingolimod, which works by preventing immune cells from leaving the lymph nodes and entering the brain and spinal cord.

Multiple Sclerosis treatment

Multiple Sclerosis treatment

Multiple Sclerosis treatment

One of the challenges of conducting clinical trials for MS treatments in Latin America is the diversity of the population and the variability of the disease across different regions. MS is more common in certain regions of the world, such as northern Europe, and may present differently in patients of different ethnicities. Researchers must take these factors into account when designing and conducting clinical trials.

Despite these challenges, there is a growing awareness and interest in MS research and treatment in Latin America. Many countries in the region have established national MS societies and patient organizations, which work to raise awareness of the disease and provide support and advocacy for patients and their families.

In addition, there is a growing network of MS clinics and centers of excellence across Latin America. These centers provide specialized care and treatment for MS patients, as well as opportunities for participation in clinical trials and research studies.

The development of effective treatments for MS is a critical goal for researchers and clinicians around the world. With ongoing clinical trials in Latin America and other regions, there is hope that new and more effective treatments will be developed in the coming years.

In conclusion, the ongoing clinical trials for MS treatments in Latin America represent an important step forward in the fight against this debilitating disease. With the development of new and more effective treatments, it is hoped that MS patients in the region and around the world will be able to live longer, healthier, and more fulfilling lives.

Multiple Sclerosis treatment

Source: Mayo Clinic

Welcome to Cohortias!

of Latin America

Simplify Your Clinical Trials with Our Expert Infrastructure in Latin America

Say goodbye to the complex, costly, and disorganized process of conducting clinical trials. Our infrastructure in Latin America streamlines the launch of studies and ensures adherence to international standards. Schedule a call with us today to discover the path to simplified clinical research in Latin America.

Multiple Sclerosis treatment

Explore What We Are Doing Better

We define ourselves as a unique team, capable of blending our academic background with a global business mindset to bring the highest standard of quality and operational excellence into clinical research in Latin America.

Early Phase Trials

- First-in-Human Studies.
- Get to patients faster, no IND necessary.
- Valid data for FDA submission.

Rescue Studies

- Regain lost time and boost patient recruitment.
- We work alongside Global CROs to get studies back on track.
- More than 200 sites available.

Phase II & III Trials

- Full-Service Clinical Outsourcing.
- Proven infrastructure that can handle any trial.
- Local Regulatory Experts
- Wide network of sites and physicians.

Medical Devices

- A fast-track platform that will meet your timeline.
- We take care of everything, from shipping requirements all the way to data collection.
Multiple Sclerosis treatment

Full Service CRO in LATAM

Outsourcing Clinical Trials to Latin America

Unlock the advantages and opportunities of outsourcing clinical trials to Latin America. Diverse patient population, streamlined regulations, and cost-effectiveness

Lower Operating Costs

From lower labor costs to lower costs for rent, utilities, and equipment, you can save money on your clinical trial budget while still ensuring the quality of your trial

Access to Emerging Markets

Latin America offers access to emerging markets, providing an opportunity for pharmaceutical companies to expand their reach and reach new patient populations.

Multiple Sclerosis treatment

Cohortias is redefining Clinical Research in Latin America

We are committed to become leaders in providing clinical research services in Latin America. Here at Cohortias, we combine our academic roots, proven experience and a large pool of patients from an extensive network of sites.

Our main purpose is to deliver high quality data.

Multiple Sclerosis treatment

Clinical Research in Latin America

Cohortias has built an extensive and highly reputable network of clinical sites which can access patients in a timely manner and operate within a standard-of-care comparable to the U.S. healthcare system.


  • Site Management

  • Data Management

  • Site Selection

  • Regulatory Submissions

  • Clinical Monitoring

  • Protocol Development


Beta Trials Platform

  • First-in-human studies

Medical Devices

  • Pilot and Pivotal Device Studies

Phases I – III

  • We partner with our clients to bring their products in a fast and efficient manner to the market with the highest quality standards


  • Diabetes/Metabolic Syndromes
  • Infectious Diseases
  • Cardiovascular
  • Neurology
  • Respiratory
  • Oncology

Multiple Sclerosis treatment

Clinical Research in Latin America

Academic Leadership and Extensive Clinical Site Network for Efficient Clinical Trials

  • Our peer-to-peer management approach guarantees high patient recruitment and retention in any clinical trial

High Speed Execution

  • We offer the quickest start-up times in each country.
  • Efficient Clinical Site Selection and Contracting.
  • Benefit from our extensive network of clinical sites and streamlined contracting process.

Operational Excellence

  • Proven record of delivering rescue studies, we consistently exceed industry performance standards.
  • Our team provides efficient query resolution to keep your trial on track.

Business Insight and Flexibility

  • We offer innovative pricing models and short lines of communication to ensure maximum flexibility and cost-effectiveness.
  • At Cohortias, we prioritize  short lines of communication to ensure efficient collaboration.
  • Swift adaptation to changes in the trial landscape to keep your study on schedule.

Multiple Sclerosis treatment

We provide our services with offices in:

Colombia &

Daniela Maresca
Daniela Maresca | Country Lead Argentina
Martín Hernández-Torre | CMO
Maritza Rojas | CRA II
Pedro Alvarez | Business Development Manager
Samantha Rodriguez Cohortias
Samantha Rdz. | Start-Up Manager
Multiple Sclerosis treatment

The Cohortias Team

Multiple Sclerosis treatment

As the largest South American Contract research Organization, we know the Advantages and Challenges Of the Region

Let Us Guide You Through The Latin American Clinical Research Landscape

Multiple Sclerosis treatment

Network & Partnerships